Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Tuberculosis Contact Investigations — United States, 2003–2012

Kai H. Young, MPH1; Melissa Ehman, MPH2; Randall Reves, MD3; Brandy L. Peterson Maddox, MPH1; Awal Khan, PhD1; Terence L. Chorba, MD1; John Jereb, MD1

Mycobacterium tuberculosis is transmitted through the air from an infectious patient (index patient) to other persons (contacts) who share space. Exposure to M. tuberculosis can result in tuberculosis (TB) disease or latent TB infection (LTBI), which has no clinical symptoms or radiologic evidence of disease. The cycle of transmission can be ended by isolating and treating patients with TB disease, examining contacts, and treating LTBI to prevent progression to TB disease. CDC systematically collects aggregate data on contact investigations from the 50 states, the District of Columbia (DC), and Puerto Rico. Data from 2003–2012 were analyzed for trends in yields from contact investigations, in terms of numbers of contacts elicited and examined and the estimated number of TB cases averted through treatment of LTBI among contacts in 2012. During 2003–2012, the number of TB cases decreased, while the number of contacts listed per index patient with contacts elicited increased. In 2012, U.S. public health authorities reported 9,945 cases of TB disease (1) and 105,100 contacts. Among these contacts, 84,998 (80.9%) were examined; TB was diagnosed in 532 (0.6%) and LTBI in 15,411 (18.1%). Among contacts with LTBI, 10,137 (65.8%) started treatment, and 6,689 (43.4% of all contacts with LTBI) completed treatment. By investigating contacts in 2012, an estimated 128 TB cases (34% of all potential cases) over the initial 5 years were averted, but an additional 248 cases (66%) might have been averted if all potentially contagious TB patients had contacts elicited, all contacts were examined, and all infected contacts completed treatment. Enhancing contact investigation activities, particularly by ensuring completion of treatment by contacts recently infected with M. tuberculosis, is essential to achieve the goal of TB elimination.

The reporting system for TB contact investigations is designed to document workload and productivity of state and local health departments (2). Contact classification and instructions for reporting are described in a user's manual and national guidelines (3,4). Data are collected based on the cascade of contact investigation activities, from eliciting contacts through completing treatment for LTBI. The reporting cycle lasts more than 2 years, reflecting the time required for investigation and completion of interventions (24). The data, aggregated at the reporting jurisdiction, are grouped into three categories based on the expected infectiousness of index patients: 1) sputum smear-positive pulmonary TB (i.e., presence of acid-fast bacilli on sputum-smear microscopy), 2) sputum smear-negative, but culture-positive pulmonary TB, and 3) all other cases and investigations (e.g., source-case investigations or investigations conducted to find persons who might have been infected from the same source as an index case) (3,4). The number and types of index patients investigated in the third category are not reported nationally because of jurisdictional variations in policy and practice (3).

For the period 2003–2012, data from 44 states and Puerto Rico were examined for trends; jurisdictions with gaps in annual reporting were excluded from this analysis. For 2012, data from all 50 states, DC, and Puerto Rico were summarized. To calculate the number of TB cases that were averted by treating LTBI diagnosed during contact investigations in 2012, an estimated 2.4% (95% confidence interval [CI] = 1.2%–4.7%) cumulative 5-year incidence without treatment (5) was used, discounted for an estimated 80% treatment effectiveness (based on findings of efficacy in clinical trials) (6). Incomplete treatment of LTBI was considered equivalent to no treatment. Missed opportunities for prevention were calculated by projecting the number of missed contacts from patients with no contact elicited or outcomes at each step of the contact investigation by the observed proportions. The projections for completing treatment were discounted by the observed proportions of patients not completing for reasons of death, adverse medication effects, health care provider decisions to discontinue treatment, and development of TB disease.

During 2003–2012, the 44 states and Puerto Rico reported 114,003 TB cases in surveillance, accounting for 90.2% of all TB cases reported in the United States and Puerto Rico (1). During this time, the number of index patients in the 44 states and Puerto Rico decreased while the number of contacts listed per index patient with contacts elicited increased from 14.9 to 21.3 contacts for sputum smear-positive index patients (Table 1). The percentage of index patients with no contact elicited decreased overall, from 7.2% in 2003 to 5.1% in 2012 for smear-positive patients and from 18.6% to 11.3% for smear-negative, culture-positive patients. The percentage of contacts who were fully examined remained stable at approximately 80%. The prevalence rates of both TB disease and LTBI decreased among contacts of smear-positive and smear-negative, culture-positive index patients. However, the yields of TB and LTBI diagnosed among contacts per index patient with contacts elicited remained stable, with an average of 0.11 contacts with TB disease and 3.13 contacts with LTBI per smear-positive index patient and 0.05 contacts with TB disease and 1.30 contacts with LTBI per smear-negative, culture-positive index patient with contacts elicited. Among contacts of smear-positive index patients who had a diagnosis of LTBI, the treatment completion rate remained stable as well, averaging 46.4% over the 10-year period. The pattern was similar for contacts of smear-negative, culture-positive index patients (Table 1).

During 2003–2012, the reason for not completing treatment was reported for 33,012 (78.8%) of 41,886 contacts who started, but did not complete treatment for LTBI, from all three categories of investigations. These reasons are mutually exclusive; if multiple factors were involved, the following hierarchy was applied: died (201; 0.6%), TB disease developed (215; 0.7%), adverse effect of treatment (2,263; 6.9%), health care provider decision (1,859; 5.6%), individual decision (15,173; 46.0%), moved and outcome was unavailable (3,240; 9.8%), or lost to follow-up (10,061; 30.5%).

In 2012, health departments in all 50 states, DC, and Puerto Rico reported 105,100 contacts (Table 2). Contact investigations of sputum smear-positive index patients yielded higher numbers of contacts elicited (21.2), TB disease diagnoses (0.11), and LTBI diagnoses (3.26) per index patient with contacts elicited than did investigations of sputum smear-negative, culture-positive index patients (11.3 contacts elicited, 0.05 TB disease diagnoses, and 1.45 LTBI diagnoses per index patient with contacts elicited). Among sputum smear-negative, culture-positive index patients, 12.1% had no contacts elicited, compared with 5.5% of sputum smear-positive index patients. The number of contacts with TB disease and LTBI diagnoses per smear-positive index patient with contacts elicited was more than twice the number per smear-negative, culture-positive index patient with contacts elicited.

Based on TB contact investigations in 2012 in all 50 states, DC, and Puerto Rico, a projected estimate of 128 (CI = 64–252) TB cases were averted over a 5-year span by treating 6,689 contacts with LTBI (Table 3). An estimated additional 248 TB cases could have been averted by initiation and completion of LTBI treatment among missed contacts, contacts who were not examined, and those who did not start or complete treatment because the patient moved, was lost to follow-up, or chose to stop treatment. Overall, contact investigations resulted in the diagnosis of TB in 532 (76%) of 697 contacts projected to have TB disease and averted an estimated 128 (34%) of the 376 TB cases that could have been averted in the initial 5-year period, if every possible intervention had been completed.

Discussion

Although the number of TB cases in 44 states and Puerto Rico and the percentage of index patients with no contacts elicited declined from 2003 to 2012, the percentage of contacts who were examined did not change, and fewer than half of contacts who received a diagnosis of LTBI completed treatment. In 2012, contacts outnumbered TB cases almost 11 to 1 in the United States, which indicates a burden of public health work that is not evident from TB case counts alone, and is thus not apparent to the public or to policy makers. TB contact investigations are complex interventions, lasting more than 2 years and requiring specialized skills (4). For example, after public health authorities assess the contagious period of an index TB patient, a list of contacts is elicited by 1) interviewing the index patient or proxies, 2) reviewing administrative records in congregate settings (e.g., schools), and 3) visiting sites frequented by the index patient (4). The procedures required to confirm TB disease or LTBI can take up to 3 months. The most common regimen for treating LTBI has been daily isoniazid for 9 months, with monthly health care visits for monitoring treatment (4).

Because the rate of developing TB disease is highest in the first 2 years following infection, as are the opportunities for preventing TB (48), TB contact investigations are efficient for finding previously undiagnosed cases and detecting newly acquired LTBI. For the period 2003–2012, for every smear-positive TB patient with contacts elicited, an average of three contacts with LTBI were found, and for every 10 smear-positive TB patients with contacts elicited, one contact had TB disease. Among all contacts who were examined from 2003 to 2012, 0.7% received a diagnosis of TB disease, a percentage slightly smaller than the 1%–3% reported globally in epidemiologic studies (7). Since 2012, the World Health Organization has recommended contact investigations as part of the global TB control strategy, focusing on the most vulnerable contacts with the most intense exposure for low-resource settings (8). For settings with more resources, larger and more intensive contact investigations are recommended (4,8).

The estimate of 128 potential TB cases averted through treatment of LTBI in TB contact investigations in 2012 is conservative. The risk for TB developing without treatment extends for the lifetime of infected contacts, far beyond this estimate of cases averted during the first 5 years after infection. Further, this estimate does not include any projections of cases averted from secondary transmission or partial effectiveness of LTBI treatment among patients who started but did not complete treatment.

The findings in this report are subject to at least three limitations. First, the reports contain no information about whether all persons who were included as contacts had significant exposure to the index patient, or whether all persons who were exposed were included as contacts in the investigations. Second, the data are not linked to the index TB cases reported to the National Tuberculosis Surveillance System (1). Finally, data are not externally validated, and risk stratification (e.g., for HIV infection) is not possible nationally because the data are aggregated before they are sent to CDC. Nonetheless, the overall U.S. findings are similar to those from studies using a variety of methods (1,4,6).

Contact investigations in the United States are not achieving their full potential for preventing TB because of shortfalls at several junctures. First, contacts were not elicited for one in 13 potentially infectious (smear-positive or smear-negative, culture-positive) index patients in 2012. Although contact elicitation has improved over the years, and success could be attributed to the guidance encouraging prioritization of activities based on the infectiousness of index patients (4), efforts should be made to ensure that contacts are elicited from all potentially infectious patients. Second, one in five contacts were not examined. Third, more than half of infected contacts did not complete a regimen for preventing TB. Treatment is recommended for all contacts who have LTBI (4), but one third of persons with LTBI did not start treatment, possibly because of patient or health care provider misperceptions about risks and benefits of treatment for LTBI (4,6,8). Furthermore, one third of all infected contacts who started treatment did not complete it.

A major barrier to completing treatment has been the 9-month isoniazid regimen. A briefer combination regimen of isoniazid-rifapentine administered once a week as directly observed therapy over 12 weeks, which some health departments began to implement in 2012, can increase treatment initiation and completion rates (9), and innovative case management strategies building on collaborations between health care systems could minimize loss to follow-up and ensure treatment completion. Increasing the treatment of LTBI for multiple risk groups, including contacts recently infected with M. tuberculosis, is essential for achieving TB elimination (10).

Acknowledgments

State and local TB control officials; Linda Leary; Division of Tuberculosis Elimination program consultants.

1Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC; 2Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health; 3Denver Public Health Department.

Corresponding author: Kai H. Young, deq0@cdc.gov, 404-639-2217.

References

  1. CDC. Reported tuberculosis in the United States, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/tb/statistics/reports/2012/pdf/report2012.pdf.
  2. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003;7(Suppl 3):S384–90.
  3. CDC. Aggregate reports for tuberculosis program evaluation: training manual and users guide. Atlanta, GA: US Department of Health and Human Services, CDC; 2005. Available at http://www.cdc.gov/tb/publications/pdf/arpes_manualsm1.pdf.
  4. CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54(No. RR-15).
  5. Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014;190:1044–52.
  6. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010;15:603–22.
  7. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 2013;41:140–56.
  8. World Health Organization. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva, Switzerland: World Health Organization; 2012. Available at http://apps.who.int/iris/bitstream/10665/77741/1/9789241504492_eng.pdf?ua=1.
  9. CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011;60:1650–3.
  10. Hill AN, Becerra J, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect 2012;140:1862–72.

Summary

What is already known on this topic?

Tuberculosis (TB) disease is spread person-to-person by the airborne route. Investigating contacts of contagious TB patients, a globally recommended strategy, finds new TB cases. Additional cases can be prevented by treating contacts who have latent TB infection (LTBI).

What is added by this report?

From 2003 to 2012, the number of TB cases decreased, while the number of contacts listed per index patient with contacts elicited increased. For 2012, the United States reported an average of 11 contacts for every TB case counted (21 contacts for each of the most contagious TB patients with contacts elicited). Approximately 1% of contacts already had TB at the time of examination. An estimated 128 cases over 5 years were averted by treating LTBI among contacts in 2012. However, an additional 248 cases could have been prevented if all infectious TB patients had contacts identified, all contacts received a medical examination, and contacts with LTBI started and completed treatment.

What are the implications for public health practice?

TB contact investigations in the United States are productive. The workload and yield of TB contact investigations are not reflected in the number of cases that are routinely reported in TB surveillance. Increasing the number of contacts with LTBI diagnoses who start and complete treatment would considerably reduce the number of TB cases in the United States.


TABLE 1. Results of tuberculosis contact investigations — 44 states* and Puerto Rico, 2003–2012

Patient classification/Year

No. of index patients for investigation

No. of patients with no contacts elicited (%)

Total no. of contacts elicited

No. of contacts examined (%)

No. of contacts with TB diagnosis (%)

No. of contacts with LTBI diagnosis (%§)

No. with LTBI who initiated treatment (%)

No. with LTBI who completed treatment (%)

Yields per patient with contacts elicited

Contacts elicited

TB diagnoses

LTBI diagnoses

Smear-positive**

41,646

2,689 (6.5)

692,672

569,526 (82.2)

4,307 (0.8)

121,837 (21.4)

86,975 (71.4)

56,514 (46.4)

17.8

0.11

3.13

2003

4,928

355 (7.2)

67,919

55,031 (81.0)

530 (1.0)

14,301 (26.0)

10,599 (74.1)

6,317 (44.2)

14.9

0.12

3.13

2004

5,020

356 (7.1)

78,322

64,953 (82.9)

491 (0.8)

15,396 (23.7)

10,851 (70.5)

6,669 (43.3)

16.8

0.11

3.30

2005

4,397

308 (7.0)

63,652

52,708 (82.8)

449 (0.9)

12,267 (23.3)

8,611 (70.2)

5,498 (44.8)

15.6

0.11

3.00

2006

4,619

353 (7.6)

70,103

56,483 (80.6)

371 (0.7)

12,241 (21.7)

8,952 (73.1)

5,931 (48.5)

16.4

0.09

2.87

2007

4,312

276 (6.4)

68,964

56,869 (82.5)

414 (0.7)

12,861 (22.6)

9,039 (70.3)

6,201 (48.2)

17.1

0.10

3.19

2008

4,326

325 (7.5)

75,759

62,270 (82.2)

438 (0.7)

12,400 (19.9)

8,793 (70.9)

5,625 (45.4)

18.9

0.11

3.10

2009

3,665

202 (5.5)

66,112

55,314 (83.7)

354 (0.6)

10,594 (19.2)

7,699 (72.7)

5,206 (49.1)

19.1

0.10

3.06

2010

3,532

178 (5.0)

63,795

53,068 (83.2)

485 (0.9)

10,495 (19.8)

7,702 (73.4)

5,257 (50.1)

19.0

0.14

3.13

2011

3,532

167 (4.7)

70,935

57,424 (81.0)

438 (0.8)

11,003 (19.2)

7,806 (70.9)

5,244 (47.7)

21.1

0.13

3.27

2012

3,315

169 (5.1)

67,111

55,406 (82.6)

337 (0.6)

10,279 (18.6)

6,923 (67.4)

4,566 (44.4)

21.3

0.11

3.27

Smear-negative, culture-positive††

23,549

3,231 (13.7)

188,422

152,877 (81.1)

915 (0.6)

26,424 (17.3)

17,846 (67.5)

11,745 (44.4)

9.3

0.05

1.30

2003

2,710

505 (18.6)

18,833

15,260 (81.0)

111 (0.7)

2,959 (19.4)

2,203 (74.5)

1,324 (44.7)

8.5

0.05

1.34

2004

2,672

392 (14.7)

21,425

16,979 (79.2)

108 (0.6)

3,386 (19.9)

2,405 (71.0)

1,504 (44.4)

9.4

0.05

1.49

2005

2,390

345 (14.4)

20,613

16,523 (80.2)

93 (0.6)

2,688 (16.3)

1,857 (69.1)

1,225 (45.6)

10.1

0.05

1.31

2006

3,137

362 (11.5)

19,909

16,051 (80.6)

92 (0.6)

2,933 (18.3)

1,998 (68.1)

1,336 (45.6)

7.2

0.03

1.06

2007

3,023

341 (11.3)

18,901

15,629 (82.7)

73 (0.5)

2,898 (18.5)

1,976 (68.2)

1,406 (48.5)

7.0

0.03

1.08

2008

2,261

414 (18.3)

22,082

18,037 (81.7)

103 (0.6)

2,808 (15.6)

1,805 (64.3)

1,169 (41.6)

12.0

0.06

1.52

2009

1,991

271 (13.6)

16,778

14,007 (83.5)

92 (0.7)

2,135 (15.2)

1,505 (70.5)

1,010 (47.3)

9.8

0.05

1.24

2010

1,937

220 (11.4)

17,850

14,631 (82.0)

90 (0.6)

2,220 (15.2)

1,445 (65.1)

990 (44.6)

10.4

0.05

1.29

2011

1,810

198 (10.9)

15,666

12,717 (81.2)

83 (0.7)

2,291 (18.0)

1,398 (61.0)

930 (40.6)

9.7

0.05

1.42

2012

1,618

183 (11.3)

16,365

13,043 (79.7)

70 (0.5)

2,106 (16.1)

1,254 (59.5)

851 (40.4)

11.4

0.05

1.47

Others§§

163,150

135,404 (83.0)

1,013 (0.7)

21,071 (15.6)

14,329 (68.0)

9,005 (42.7)

2003

19,941

16,914 (84.8)

100 (0.6)

2,831 (16.7)

2,004 (70.8)

1,212 (42.8)

2004

20,005

16,589 (82.9)

166 (1.0)

3,052 (18.4)

2,123 (69.6)

1,244 (40.8)

2005

18,761

16,053 (85.6)

89 (0.6)

2,148 (13.4)

1,459 (67.9)

908 (42.3)

2006

15,839

13,199 (83.3)

84 (0.6)

1,911 (14.5)

1,157 (60.5)

731 (38.3)

2007

16,431

12,339 (75.1)

103 (0.8)

1,894 (15.3)

1,345 (71.0)

872 (46.0)

2008

16,067

13,917 (86.6)

85 (0.6)

2,061 (14.8)

1,368 (66.4)

809 (39.3)

2009

12,210

10,349 (84.8)

82 (0.8)

1,618 (15.6)

1,133 (70.0)

735 (45.4)

2010

17,755

14,699 (82.8)

134 (0.9)

2,018 (13.7)

1,445 (71.6)

980 (48.6)

2011

14,477

11,985 (82.8)

107 (0.9)

2,002 (16.7)

1,338 (66.8)

902 (45.1)

2012

11,664

9,360 (80.2)

63 (0.7)

1,536 (16.4)

957 (62.3)

612 (39.8)

Abbreviations: LTBI = latent TB infection; TB = tuberculosis disease.

* Excludes Georgia, Louisiana, Pennsylvania, Washington, Wisconsin, Wyoming, and the District of Columbia because reports for some years were unobtainable.

As percentages of the numbers in the preceding column.

§ As percentages of the number of contacts who were examined.

As percentages of the number of contacts with LTBI.

** Smear-positive: pulmonary index patients with acid-fast bacilli reported from sputum-smear microscopy.

†† Smear-negative, culture-positive: pulmonary index patients without acid-fast bacilli reported from sputum-smear microscopy but with Mycobacterium tuberculosis isolated by culture.

§§ Others: TB patient contact investigations conducted for reasons determined by local policy, such as source-case investigations or investigations conducted to find persons who might have been infected from the same source as an index patient.


TABLE 2. Results of tuberculosis contact investigations — United States* and Puerto Rico, 2012

Patient classification

No. of index patients for investigation

No. of patients with no contacts elicited (%)

Total no. of contacts elicited

No. of contacts examined (%)

No. of contacts with TB diagnosis (%)

No. of contacts with LTBI diagnosis (%§)

No. with LTBI who initiated treatment (%)

No. with LTBI who completed treatment (%)

Yields per patient with contacts elicited

Contacts elicited

TB diagnoses

LTBI diagnoses

Smear-positive**

3,681

201 (5.5)

73,602

60,120 (81.7)

380 (0.6)

11,337 (18.9)

7,668 (67.6)

5,052 (44.6)

21.2

0.11

3.26

Smear-negative, culture-positive††

1,840

223 (12.1)

18,233

14,311 (78.5)

83 (0.6)

2,340 (16.4)

1,384 (59.1)

945 (40.4)

11.3

0.05

1.45

Others§§

13,265

10,567 (79.7)

69 (0.7)

1,734 (16.4)

1,085 (62.6)

692 (39.9)

Total

105,100

84,998 (80.9)

532 (0.6)

15,411 (18.1)

10,137 (65.8)

6,689 (43.4)

Abbreviations: LTBI = latent TB infection; TB = tuberculosis disease.

* Includes all 50 states and the District of Columbia.

As percentages of the numbers in the preceding column.

§ As percentages of the number of contacts who were examined.

As percentages of the number of contacts with LTBI.

** Smear-positive: pulmonary index patients with acid-fast bacilli reported from sputum-smear microscopy.

†† Smear-negative, culture-positive: pulmonary index patients without acid-fast bacilli reported from sputum-smear microscopy but with Mycobacterium tuberculosis isolated by culture.

§§ Others: TB patient contact investigations conducted for reasons determined by local policy, such as source-case investigations or investigations conducted to find persons who might have been infected from the same source as an index patient.


TABLE 3. Projected number of tuberculosis cases averted by contact investigations and number of missed opportunities to avert additional cases — United States* and Puerto Rico, 2012

Patient classification

Reported counts

Total no. contacts elicited

No. of contacts examined

No. of contacts with TB diagnosis

No. of contacts with LTBI diagnosis

No. with LTBI who initiated treatment

No. with LTBI who completed treatment

Projected no. TB cases averted (95% CI)

Smear-positive§

Results from investigations

73,602

60,120

380

11,337

7,668

5,052

97 (48–190)

Missed opportunities, total

177 (88–346)

Patients with no contacts elicited

201

4,261

4,261

26

805

805

770

15 (7–29)

Contacts not examined

13,482

13,482

81

2,548

2,548

2,436

47 (23–92)

Contacts with LTBI, did not initiate treatment

3,669

3,669

3,508

67 (34–132)

Contacts with LTBI, initiated treatment, not completed**

2,616

2,501

48 (24–94)

Smear-negative, culture-positive††

Results from investigations

18,233

14,311

83

2,340

1,384

945

18 (9–36)

Missed opportunities, total

44 (22–85)

Patients with no contacts elicited

223

2,520

2,520

15

413

413

387

7 (4–15)

Contacts not examined

3,922

3,922

24

643

643

603

12 (6–23)

Contacts with LTBI, did not initiate treatment

956

956

897

17 (9–34)

Contacts with LTBI, initiated treatment, not completed**

439

412

8 (4–15)

Others§§

Results from investigations

13,265

10,567

69

1,734

1,085

692

13 (7–26)

Missed opportunities, total

27 (14–53)

Contacts not examined

2,698

2,698

19

442

442

418

8 (4–16)

Contacts with LTBI, did not initiate treatment

649

649

613

12 (6–23)

Contacts with LTBI, initiated treatment, not completed**

393

371

7 (4–14)

Total projected outcomes from investigations and estimated missed opportunities¶¶

111,881

109,361

697

20,262

20,262

19,605

376 (189–737)

Results from investigations

105,100

84,998

532

15,411

10,137

6,689

128 (64–252)

Total missed opportunities

6,781

24,363

165

4,851

10,125

12,916

248 (125–486)

Abbreviations: CI = confidence interval; LTBI = latent TB infection; TB = tuberculosis disease.

* Includes all 50 states and the District of Columbia.

Number of TB cases averted = number of contacts with LTBI who completed treatment multiplied by 2.4% (cumulative 5-year incidence without treatment) and 80.0% (estimated treatment effectiveness).

§ Smear-positive: pulmonary index patients with acid-fast bacilli reported from sputum-smear microscopy.

Missed opportunities for prevention: potential number of contacts elicited = number of patients with no contact elicited multiplied by the number of contacts elicited per index patient investigated (21.2 for smear-positive, 11.3 for smear-negative, culture-positive index patient investigated); potential number of contacts examined = number of contacts elicited (assuming all contacts elicited are examined); potential number of contacts with TB diagnosis = number of contacts not examined multiplied by 0.6% (proportion with TB diagnosis among contacts of smear-positive, or smear-negative, culture-positive patients) or 0.7% (among other contacts); potential number of contacts with LTBI diagnosis = number of contacts not examined multiplied by 18.9% (proportion with LTBI diagnosis among contacts of smear-positive patients) or 16.4% (among contacts of smear-negative, culture-positive patients, or other contacts); potential number contacts with LTBI who initiated treatment = number with LTBI diagnosis (assuming all contacts diagnosed with LTBI initiate treatment) or number with LTBI who did not initiate treatment; potential number of contacts with LTBI who completed treatment = number with LTBI who initiated treatment, or number of LTBI who initiated treatment, but did not complete, subtracting the proportion not completing for reasons of death, adverse effects, health care provider decisions to discontinue treatment, and TB disease developed (4.4% for contacts of smear-positive patients, 6.2% for contacts of smear-negative, culture-positive patients, and 5.5% for other contacts).

** Includes contacts who moved, were lost to follow-up, or decided to stop treatment.

†† Smear-negative, culture-positive: pulmonary index patients without acid-fast bacilli reported from sputum-smear microscopy but with Mycobacterium tuberculosis isolated by culture.

§§ Others: TB patient contact investigations conducted for reasons determined by local policy, such as source-case investigations or investigations conducted to find persons who might have been infected from the same source as an index patient.

¶¶ Projected outcomes from investigations are the sum of results from investigations and the estimated missed opportunities from each step of the contact investigation process.



Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #